In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Example Input: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Accurate Education for Prenatal
Screenings Act''.

SEC. 2. CELL-FREE DNA PRENATAL SCREENING EDUCATION PROGRAMS.

Part B of title III of the Public Health Service Act is amended by
inserting, after section 317T (42 U.S.C. 247b-22), the following:

''SEC. 317U. CELL-FREE DNA PRENATAL SCREENING EDUCATION PROGRAMS.

''(a) Education Programs.--With respect to cell-free DNA prenatal
screening, the Secretary, acting through the Director of the Centers
for Disease Control and Prevention, shall develop, implement, and
maintain two programs, one for patients and one for health care
providers, to educate patients and health care providers regarding
matters including--
''(1) the purposes and definitions of such screenings;
''(2) the reasons for patients and health care providers to
consider such screenings;
''(3) the conditions such screenings may detect, including
accurate and up-to-date information about such conditions'
clinical features, prognoses, and treatments according to
relevant national disability organizations and medical
professional societies;
''(4) the risks and benefits of, and alternatives to, the
various methods of administering such screenings and prenatal
diagnostic testings, including the option to forego such
screenings and testings, as per guidelines established by
medical professional societies;
''(5) the possible results of such screenings;
''(6) the accuracy of the results of such screenings,
including positive predictive value, negative predictive value,
specificity, sensitivity, the inability of such screenings to
reliably diagnose chromosomal abnormalities, and the fact that
such screenings may yield false-positive and false-negative
results;
''(7) the need for diagnostic testing, and counseling by a
genetics professional, for patients whose screenings yield
positive, abnormal, or indeterminate results; and
''(8) the need for communication of screening results to
patients and appropriate follow up per guidelines established
by medical professional societies.
''(b) Materials.--Each program developed under this section shall
include the provision of materials that--
''(1) contain information that is peer-reviewed, balanced,
accurate, and up-to-date;
''(2) enable the respective target audience to understand
the available options with regards to cell-free DNA prenatal
screenings, other prenatal screenings, and diagnostic tests;
''(3) promote the informed consent, and enhance the
decision-making processes of, the respective target audience
before and after such screenings;
''(4) contain information that appropriately addresses the
diversity of the patient population, including patients
proficient in languages other than English; and
''(5) contain contact information for relevant services and
support organizations for patients.
''(c) Assessment.--In developing, implementing, and maintaining
programs and materials under this section, the Secretary, acting
through the Director of the Centers for Disease Control and Prevention,
shall--
''(1) consult with relevant medical professional,
disability support, patient advocacy, parents, and genetics
professionals organizations;
''(2) consult with companies and laboratories that perform
cell-free DNA prenatal screenings or develop the technologies
for such screenings;
''(3) assess and evaluate existing education activities and
materials for health care providers and patients related to
such screenings; and
''(4) take the results of such consultations, assessment,
and evaluation into account in developing educational programs
and materials under this section.
''(d) Annual Report.--Not later than 16 months after the date of
enactment of this section and annually thereafter, the Secretary shall
submit a progress report to the Congress with respect to--
''(1) the development and implementation of the education
programs established under this section;
''(2) the accessibility of each program to its respective
target audience;
''(3) the adoption of each program by its respective target
audience; and
''(4) the Secretary's efforts to ensure health care
providers and patients receive the materials created pursuant
to this section.
''(e) Deadline.--The Secretary shall develop and implement the
education programs required by section 317U of the Public Health
Service Act (as added by subsection (a)) not later than 1 year after
the date of enactment of this Act''.
Example Output: Accurate Education for Prenatal Screenings Act Amends the Public Health Service Act to direct the Centers for Disease Control and Prevention (CDC) to develop, implement, and maintain two programs, one to educate patients and one to educate health care providers regarding: the purposes and definitions of cell-free DNA prenatal screenings; the reasons for patients and providers to consider such screenings; the conditions such screenings may detect; the risks and benefits of, and alternatives to, the various methods of administering such screenings and prenatal diagnostic testing; the possible results of such screenings and the accuracy of such results; the need for diagnostic testing, and counseling by a genetics professional, for patients whose screenings yield positive, abnormal, or indeterminate results; and the need for communication of results to patients and appropriate follow-up per guidelines established by medical professional societies. Requires each program to provide materials that: contain information that is peer-reviewed, balanced, accurate, and up-to-date; enable the respective target audience to understand the available options with regard to such screenings, other prenatal screenings, and diagnostic tests; promote the informed consent of, and enhance the decision-making processes of, the respective target audience before and after such screenings; contain information that appropriately addresses the diversity of the patient population; and contain contact information for relevant services and support organizations for patients. Requires CDC to submit annual reports regarding: the development and implementation of such programs; the accessibility of each program to, and the adoption of each program by, its respective target audience; and CDC's efforts to ensure that providers and patients receive the materials created pursuant to this Act.

Example Input: SECTION 1. DEVELOPMENT OF BEST PRACTICES FOR THE USE OF PRESCRIPTION
OPIOIDS.

(a) Definitions.--In this section--
(1) the term ''Secretary'' means the Secretary of Health
and Human Services; and
(2) the term ''task force'' means the Pain Management Best
Practices Inter-Agency Task Force convened under subsection
(b).
(b) Inter-Agency Task Force.--Not later than December 14, 2018, the
Secretary, in cooperation with the Secretary of Veterans Affairs, the
Secretary of Defense, and the Administrator of the Drug Enforcement
Administration, shall convene a Pain Management Best Practices Inter-
Agency Task Force to review, modify, and update, as appropriate, best
practices for pain management (including chronic and acute pain) and
prescribing pain medication.
(c) Membership.--The task force shall be comprised of--
(1) representatives of--
(A) the Department of Health and Human Services;
(B) the Department of Veterans Affairs;
(C) the Food and Drug Administration;
(D) the Department of Defense;
(E) the Drug Enforcement Administration;
(F) the Centers for Disease Control and Prevention;
(G) the Health Resources and Services
Administration;
(H) the Indian Health Service;
(I) the National Academy of Medicine;
(J) the National Institutes of Health;
(K) the Office of National Drug Control Policy;
(L) the Substance Abuse and Mental Health Services
Administration; and
(M) the Office of Women's Health;
(2) State medical boards;
(3) subject to subsection (e), physicians, dentists, and
nonphysician prescribers;
(4) hospitals;
(5) subject to subsection (e), pharmacists and pharmacies;
(6) first responders;
(7) experts in the fields of pain research and addiction
research;
(8) experts in the fields of adolescent and young adult
addiction research;
(9) representatives of--
(A) pain management professional organizations;
(B) the mental health treatment community;
(C) the addiction treatment and recovery community;
(D) pain advocacy groups;
(E) veteran service organizations; and
(F) groups with expertise on overdose reversal;
(10) a person in recovery from addiction to medication for
chronic pain;
(11) a person in recovery from addiction to medication for
chronic pain, whose addiction began in adolescence or young
adulthood;
(12) a person with chronic pain;
(13) an expert on active duty military, armed forces
personnel, and veteran health and prescription opioid
addiction;
(14) an expert in the field of minority health; and
(15) other stakeholders, as the Secretary determines
appropriate.
(d) Condition on Participation on Task Force.--An individual
representing a profession or entity described in paragraph (3) or (5)
of subsection (c) may not serve as a member of the task force unless
such individual--
(1) is currently licensed in a State in which such
individual is practicing (as defined by such State) such
profession (or, in the case of an individual representing an
entity, a State in which the entity is engaged in business);
and
(2) is currently practicing (as defined by such State) such
profession (or, in the case of an individual representing an
entity, the entity is in operation).
(e) Duties.--The task force shall--
(1) not later than 180 days after the date on which the
task force is convened under subsection (b), review, modify,
and update, as appropriate, best practices for pain management
(including chronic and acute pain) and prescribing pain
medication, taking into consideration--
(A) existing pain management research;
(B) research on trends in areas and communities in
which the prescription opioid abuse rate and fatality
rate exceed the national average prescription opioid
abuse rate and fatality rate;
(C) recommendations from relevant conferences and
existing relevant evidence-based guidelines;
(D) ongoing efforts at the State and local levels
and by medical professional organizations to develop
improved pain management strategies, including
consideration of differences within and between classes
of opioids, the availability of opioids with abuse
deterrent technology, and pharmacological,
nonpharmacological, medical device alternatives to
opioids to reduce opioid monotherapy in appropriate
cases and the coordination of information collected
from State prescription drug monitoring programs for
the purpose of preventing the diversion of pain
medication;
(E) ongoing efforts at the Federal, State, and
local levels to examine the potential benefits of
electronic prescribing of opioids, including any public
comments collected in the course of those efforts;
(F) the management of high-risk populations, other
than populations who suffer pain, who--
(i) may use or be prescribed
benzodiazepines, alcohol, and diverted opioids;
or
(ii) receive opioids in the course of
medical care;
(G) the distinct needs of adolescents and young
adults with respect to pain management, pain
medication, substance use disorder, and medication-
assisted treatment;
(H) the 2016 Guideline for Prescribing Opioids for
Chronic Pain issued by the Centers for Disease Control
and Prevention;
(I) the practice of co-prescribing naloxone for
both pain patients receiving chronic opioid therapy and
patients being treated for opioid use disorders;
(J) research that has been, or is being, conducted
or supported by the Federal Government on prevention
of, treatment for, and recovery from substance use by
and substance use disorders among adolescents and young
adults relative to any unique circumstances (including
social and biological circumstances) of adolescents and
young adults that may make adolescent-specific and
young adult-specific treatment protocols necessary,
including any effects that substance use and substance
use disorders may have on brain development and the
implications for treatment and recovery;
(K) Federal non-research programs and activities
that address prevention of, treatment for, and recovery
from substance use by and substance use disorders among
adolescents and young adults, including an assessment
of the effectiveness of such programs and activities
in--
(i) preventing substance use by and
substance use disorders among adolescents and
young adults;
(ii) treating such adolescents and young
adults in a way that accounts for any unique
circumstances faced by adolescents and young
adults; and
(iii) supporting long-term recovery among
adolescents and young adults; and
(L) gaps that have been identified by Federal
officials and experts in Federal efforts relating to
prevention of, treatment for, and recovery from
substance use by and substance use disorders among
adolescents and young adults, including gaps in
research, data collection, and measures to evaluate the
effectiveness of Federal efforts, and the reasons for
such gaps;
(2) solicit and take into consideration public comment on
the practices developed under paragraph (1), amending such best
practices if appropriate;
(3) develop a strategy for disseminating information about
the best practices developed under paragraphs (1) and (2) to
prescribers, pharmacists, State medical boards, educational
institutions that educate prescribers and pharmacists, and
other parties, as the Secretary determines appropriate;
(4) review, modify, and update best practices for pain
management and prescribing pain medication, specifically as it
pertains to physician education and consumer education; and
(5) examine and identify--
(A) the extent of the need for the development of
new pharmacological, nonpharmacological, and medical
device alternatives to opioids;
(B) the current status of research efforts to
develop such alternatives; and
(C) the pharmacological, nonpharmacological, and
medical device alternatives to opioids that are
currently available that could be better utilized.
(f) Consideration of Study Results.--In reviewing, modifying, and
updating, best practices for pain management and prescribing pain
medication, the task force shall take into consideration existing
private sector, State, and local government efforts related to pain
management and prescribing pain medication.
(g) Limitation.--The task force shall not have rulemaking
authority.
(h) Report.--Not later than 270 days after the date on which the
task force is convened under subsection (b), the task force shall
submit to Congress a report that includes--
(1) the strategy for disseminating best practices for pain
management (including chronic and acute pain) and prescribing
pain medication, as developed under subsection (e);
(2) the results of a feasibility study on linking the best
practices described in paragraph (1) to receiving and renewing
registrations under section 303(f) of the Controlled Substances
Act (21 U.S.C. 823(f));
(3) recommendations for effectively applying the best
practices described in paragraph (1) to improve prescribing
practices at medical facilities, including medical facilities
of the Veterans Health Administration and Indian Health
Service;
(4) the modified and updated best practices described in
subsection (e)(4); and
(5) the results of the examination and identification
conducted pursuant to subsection (e)(4), and recommendations
regarding--
(A) the development of new pharmacological,
nonpharmacological, and medical device alternatives to
opioids; and
(B) the improved utilization of pharmacological,
nonpharmacological, and medical device alternatives to
opioids that are currently available.

Passed the House of Representatives May 11, 2016.

Attest:

KAREN L. HAAS,

Clerk.
Example Output: (Sec. 1) This bill requires the Department of Health and Human Services to convene a Pain Management Best Practices Inter-Agency Task Force to: (1) review, modify, and update best practices for pain management and prescribing pain medication; and (2) examine and identify the need for, development of, and availability of medical alternatives to opioids (drugs with effects similar to opium, such as certain pain medications). The task force must submit a report that includes: (1) the modified and updated best practices; (2) a strategy for disseminating the best practices; (3) the feasibility of linking the best practices to Drug Enforcement Administration registration of manufacturers, distributors, and dispensers of controlled substances; (4) recommendations for effectively applying the best practices at medical facilities; and (5) recommendations regarding medical alternatives to opioids.

Example Input: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Union Member Protection Act''.

SEC. 2. FINDINGS.

Congress finds the following:
(1) Labor unions make significant political contributions
and expenditures that directly or indirectly influence the
election of candidates and support or oppose political causes.
Decisions to use union dues for political contributions and
expenditures are usually made by union leadership and
management, rather than union membership.
(2) Unions, acting through their management, should be
obligated to conduct business in the best interests of their
membership.
(3) Historically, union members have not had a way to know,
or to influence, the political activities of unions that are
supposed to represent them. Union members and the public have a
right to know how unions are spending members' dues to make
political contributions or expenditures benefitting candidates,
political parties, and political causes.
(4) Unions should be accountable to their membership in
making political contributions or expenditures affecting
Federal governance and public policy. Requiring the express
approval of a union's membership for political contributions or
expenditures will establish necessary accountability.

SEC. 3. DISCLOSURE AND APPROVAL OF CERTAIN POLITICAL EXPENDITURES.

(a) In General.--Title II of the Labor-Management Reporting and
Disclosure Act (29 U.S.C. 431 et seq.) is amended by inserting after
section 201 the following:

''SEC. 201A. DISCLOSURE AND APPROVAL OF CERTAIN POLITICAL EXPENDITURES
BY LABOR ORGANIZATIONS.

''(a) Disclosure.--The report required under section 201 shall
contain, in a clear and simple format--
''(1) a description of the specific nature of any
expenditures for political activities proposed to be made by
the labor organization for the forthcoming fiscal year, to the
extent the specific nature is known to the labor organization
and including the total amount of such proposed expenditures;
and
''(2) a disclosure of how each officer of the labor
organization voted to authorize or not to authorize each
expenditure for political activities made by the labor
organization during the preceding fiscal year.
''(b) Restriction on Expenditures.--No labor organization shall
make any expenditure for political activities in any fiscal year
unless--
''(1) such expenditure is of the nature of those proposed
by the labor organization pursuant to subsection (a); and
''(2) the full, free, and written authorization for such
expenditures has been granted by a majority of the members of
the labor organization.
''(c) Mechanism for Obtaining Authorization.--Not later than 1 year
after the date of enactment of the Union Member Protection Act, every
labor organization shall adopt a mechanism for obtaining, by secret
ballot, the authorization of its members as required under subsection
(b)(2).
''(d) Liability.--The officers of a labor organization who
authorize an expenditure without first obtaining the authorization of
members required under subsection (b)(2) shall be jointly and severally
liable in any action brought in any court of competent jurisdiction to
any member of the labor organization or class of members for the amount
of dues paid by such member or class of member during the 1 year period
prior to the date that such expenditure was made.
''(e) Definition of Expenditure for Political Activities.--As used
in this section:
''(1) The term 'expenditure for political activities'
means--
''(A) an independent expenditure, as such term is
defined in section 301(17) of the Federal Election
Campaign Act of 1971 (2 U.S.C. 431(17));
''(B) contributions to any political party,
committee, or electioneering communication, as such
term is defined in section 304(f)(3)(A) of the Federal
Election Campaign Act of 1971 (2 U.S.C. 434(f)(3)(A));
and
''(C) dues or other payments to trade associations
or other tax exempt organizations that are, or could
reasonably be anticipated to be, used for the purposes
described in subparagraph (A).
''(2) Such term shall not include--
''(A) direct lobbying efforts through registered
lobbyists employed or hired by the labor organization;
''(B) communications by a labor organization to its
members and executive or administrative personnel and
their families; or
''(C) the establishment, administration, and
solicitation of contributions to a separate segregated
fund to be utilized for political purposes by a labor
organization.''.
(b) Conforming Amendments.--
(1) Section 201(c) of such Act (29 U.S.C. 431(c)) is
amended by striking ''make available the information required
to be contained in'' and inserting ''provide''.
(2) Section 209(a) of such Act (29 U.S.C. 439(a)) is
amended by inserting ''other than section 201A'' after ''this
title''.

SEC. 4. REQUIREMENT OF VOTE BY PRINCIPAL OFFICERS.

Section 201 of the Labor-Management Reporting and Disclosure Act
(29 U.S.C. 431) is further amended by adding at the end the following:
''(f) The bylaws required under this section shall expressly
provide for a vote of the principal officers of the labor organization
on any individual expenditure for political activities (as such term is
defined in section 201A(e)) in excess of $50,000. A labor organization
shall make publicly available the individual votes of principal
officers required by the preceding sentence within 48 hours of the
vote, including in a clear and conspicuous location on the Internet
website of the labor organization.''.

SEC. 5. REPORT.

The Comptroller General of the United States shall annually conduct
a study on the compliance with the requirements of this Act by labor
organizations and their management. Not later than April 1 of each
year, the Comptroller General shall submit to Congress a report of such
study.

SEC. 6. EFFECTIVE DATE.

The amendments made by this Act shall take effect on the date of
enactment of the Shareholder Protection Act of 2010.
Example Output:
Union Member Protection Act - Amends the Labor-Management Reporting and Disclosure Act (Landrum-Griffin Act) to require a labor organization's mandatory report to the Secretary of Labor on its constitution, officers, and basic organization to include, in a clear and simple format, both: (1) a description of the specific nature and total amount of political expenditures the labor organization proposes to make for the upcoming fiscal year; and (2) a disclosure of how each labor organization officer voted on each political expenditure made by the organization during the preceding fiscal year.

Prohibits a labor organization from making political expenditures unless: (1) they are of the nature of those proposed in such report; and (2) they have received a full, free, and written authorization by secret ballot by a majority of the labor organization members.

Makes officers jointly and severally liable for authorizing a political expenditure without first obtaining the authorization of labor organization members.

Requires labor organization bylaws to provide expressly for a vote of the organization's principal officers on individual political expenditures in excess of $50,000. Requires a labor organization to make public the individual votes of such officers within 48 hours, including in a clear and conspicuous location on its website.